Key result
Combined rtPA and tirofiban linked to ~50% reduction in ischemic brain lesion volume vs rtPA alone.
Cohort (n=47)
To determine the effect of systemic thrombolysis with low-dose recombinant tissue plasminogen activator (rtPA) and the body-weight adjusted platelet GPIIb/IIIa receptor antagonist tirofiban, the authors performed lesion volumetry on magnetic resonance perfusion and diffusion images recorded before thrombolysis and on T2-weighted magnetic resonance images on day 8. Treatment with rtPA and tirofiban (n = 13) resulted in a 50% lesion reduction (p < 0.03), while lesion reduction was less in rtPA treatment (n = 16) and absent in nontreated patients (n = 18).
No takes yet. Share an insight, caveat, or question.
Seitz et al. (2004) conducted a cohort in Ischemic brain lesions (n=47). Combined thrombolysis with rtPA and tirofiban vs. rtPA alone or no treatment was evaluated on Lesion reduction on day 8 magnetic resonance imaging (p=<0.03). Treatment with combined rtPA and tirofiban resulted in a 50% reduction in ischemic brain lesion volume by day 8 (p < 0.03), greater than rtPA alone or no treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: